Stop Loss for Gene Therapy
Brent welcomes Tye Rambo, Stop Loss Business Strategy Manager, to discuss how Elevance Health is helping employers manage the financial risks of high-cost gene therapies. With one-time treatments ranging from $850,000 to over $3 million, Tye explains how Elevance’s stop loss solution ensures consistent coverage by avoiding “lasering”—a tactic that raises deductibles for known high-cost claimants. Their No New Laser protection ensures clients have predictable risk protection as groundbreaking therapies emerge. A concise, critical breakdown of how smart stop loss design can shield employer budgets while ensuring member access to life-changing treatments.